Ulcerative Colitis Patients In England Get New Treatment Option
NICE Reverses Initial Rejection Of Janssen’s Stelara
Stelara is a cost-effective use of National Health Service resources, but only where a TNF-alpha inhibitor has failed or cannot be used, and when the product is offered at the price reduction agreed with the health department’s commercial medicines arm, says the latest advice from England’s health technology assessment body, NICE. The move comes after a similar recommendation made earlier this month by NICE’s counterpart in Scotland.
You may also be interested in...
The decision by the Scottish Medicines Consortium contrasts with recent draft guidance from England’s health technology assessment body, NICE, that recommended against the National Health Service using the Janssen product for ulcerative colitis.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.